Silence Therapeutics (SLN) has released an update.
Silence Therapeutics has unveiled promising Phase 1 data for their siRNA therapy, divesiran, showing significant reductions in phlebotomy frequency and hematocrit levels in polycythemia vera patients. Following these encouraging results, the company has commenced dosing in a Phase 2 study, underscoring their commitment to advancing divesiran as a novel treatment option. With FDA Fast Track and Orphan Drug designations, Silence Therapeutics is positioning divesiran as a potential game-changer in managing this rare blood disorder.
For further insights into SLN stock, check out TipRanks’ Stock Analysis page.